Age at first birth and melanoma risk: A meta-analysis

International Journal of Clinical and Experimental Medicine

Volumn 7, Issue 12, 2014, Pages 5201-5209

  Li, Zhengyong ^a   Gu, Mingjin ^b   Cen, Ying ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Birth; Hormone; Melanoma; Meta analysis; Reproductive history

Indexed keywords

AGE; ARTICLE; CANCER RISK; CONFIDENCE INTERVAL; HAIR COLOR; MELANOMA; META ANALYSIS; RISK FACTOR; SENSITIVITY ANALYSIS; SKIN PIGMENTATION; STUDY DESIGN; SUN EXPOSURE;

EID: 84921532294     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Tomao F, Papa A, Lo Russo G, Zuber S, Spinelli GP, Rossi L, Caruso D, Prinzi N, Stati V, Benedetti Panici P, Tomao S. Correlation between fertility drugs use and malignant melanoma incidence: the state of the art. Tumour Biol 2014; [Equb ahead of print]
2. Chen ST, Geller AC, Tsao H. Update on the Epidemiology of Melanoma. Curr Dermatol Rep 2013; 2: 24-34.
3. Freedman DM, Sigurdson A, Doody MM, Rao RS, Linet MS. Risk of melanoma in relation to smoking, alcohol intake, and other factors in a large occupational cohort. Cancer Causes Control 2003; 14: 847-57.
4. Kaae J, Andersen A, Boyd HA, Wohlfahrt J, Melbye M. Reproductive history and cutaneous malignant melanoma: a comparison between women and men. Am J Epidemiol 2007; 165: 1265-70.
5. Lea CS, Holly EA, Hartge P, Lee JS, Guerry D 4th, Elder DE, Halpern A, Sagebiel RW, Tucker MA. Reproductive risk factors for cutaneous melanoma in women: a case-control study. Am J Epidemiol 2007; 165: 505-13.
6. Lens M, Bataille V. Melanoma in relation to reproductive and hormonal factors in women: current review on controversial issues. Cancer Causes Control 2008; 19: 437-42.
7. Gandini S, Iodice S, Koomen E, Di Pietro A, Sera F, Caini S. Hormonal and reproductive factors in relation to melanoma in women: Current review and meta-analysis. Eur J Cancer 2011; 47: 2607-17.
8. Beral V, Ramcharan S, Faris R. Malignant melanoma and oral contraceptive use among women in California. Br J Cancer 1977; 36: 804-9.
9. Adam SA, Sheaves JK, Wright NH, Mosser G, Harris RW, Vessey MP. A case-control study of the possible association between oral contraceptives and malignant melanoma. Br J Cancer 1981; 44: 45-50.
10. Bain C, Hennekens CH, Speizer FE, Rosner B, Willett W, Belanger C. Oral contraceptive use and malignant melanoma. J Natl Cancer Inst 1982; 68: 537-9.
11. Holly EA, Weiss NS, Liff JM. Cutaneous melanoma in relation to exogenous hormones and reproductive factors. J Natl Cancer Inst 1983; 70: 827-31.
12. Beral V, Evans S, Shaw H, Milton G. Oral contraceptive use and malignant melanoma in Australia. Br J Cancer 1984; 50: 681-5.
13. Holman CD, Armstrong BK, Heenan PJ. Cutaneous malignant melanoma in women: exogenous sex hormones and reproductive factors. Br J Cancer 1984; 50: 673-80.
14. Gallagher RP, Elwood JM, Hill GB, Coldman AJ, Threlfall WJ, Spinelli JJ. Reproductive factors, oral contraceptives and risk of malignant melanoma: Western Canada Melanoma Study. Br J Cancer 1985; 52: 901-7.
15. Green A, Bain C. Hormonal factors and melanoma in women. Med J Aust 1985; 142: 446-8.
16. Ron E, Lunenfeld B, Menczer J, Blumstein T, Katz L, Oelsner G, Serr D. Cancer incidence in a cohort of infertile women. Am J Epidemiol 1987; 125: 780-90.
17. Osterlind A, Tucker MA, Stone BJ, Jensen OM. The Danish case-control study of cutaneous malignant melanoma. III. Hormonal and reproductive factors in women. Int J Cancer 1988; 42: 821-4.
18. Adami HO, Persson I, Hoover R, Schairer C, Bergkvist L. Risk of cancer in women receiving hormone replacement therapy. Int J Cancer 1989; 44: 833-9.
19. Wyshak G, Frisch RE, Albright NL, Albright TE, Schiff I. Reproductive factors and melanoma of the skin among women. Int J Dermatol 1989; 28: 527-30.
20. Hartge P, Tucker MA, Shields JA, Augsburger J, Hoover RN, Fraumeni JF Jr. Case-control study of female hormones and eye melanoma. Cancer Res 1989; 49: 4622-5.
21. Hannaford PC, Villard-Mackintosh L, Vessey MP, Kay CR. Oral contraceptives and malignant melanoma. Br J Cancer 1991; 63: 430-3.
22. Holly EA, Aston DA, Ahn DK, Kristiansen JJ, Char DH. Uveal melanoma, hormonal and reproductive factors in women. Cancer Res 1991; 51: 1370-2.
23. Green A. Oral contraceptives and skin neoplasia. Contraception 1991; 43: 653-66.
24. Lê MG, Cabanes PA, Desvignes V, Chanteau MF, Mlika N, Avril MF. Oral contraceptive use and risk of cutaneous malignant melanoma in a case-control study of French women. Cancer Causes Control 1992; 3: 199-205.
25. Palmer JR, Rosenberg L, Strom BL, Harlap S, Zauber AG, Warshauer ME, Shapiro S. Oral contraceptive use and risk of cutaneous malignant melanoma. Cancer Causes Control 1992; 3: 547-54.
26. Zaridze D, Mukeria A, Duffy S. Risk factors for skin melanoma in Moscow. Int J Cancer 1992; 52: 159-61.
27. Zaridze DG, Mukeriia AF, Basieva TKH, Shlenskaia IN, Bukin IUV. The role of endogenous and exogenous factors in the etiology of skin melanoma. Vopr Onkol 1992; 38: 141-7.
28. Holly EA, Cress RD, Ahn DK. Cutaneous melanoma in women: ovulatory life, menopause, and use of exogenous estrogens. Cancer Epidemiol Biomarkers Prev 1994; 3: 661-8.
29. Kvåle G, Heuch I, Nilssen S. Parity in relation to mortality and cancer incidence: a prospective study of Norwegian women. Int J Epidemiol 1994; 23: 691-9.
30. Holly EA, Aston DA, Cress RD, Ahn DK, Kristiansen JJ. Cutaneous melanoma in women. II. Phenotypic characteristics and other host-related factors. Am J Epidemiol 1995; 141: 934-42.
31. Rossing MA, Daling JR, Weiss NS, Moore DE, Self SG. Risk of cutaneous melanoma in a cohort of infertile women. Melanoma Res 1995; 5: 123-7.
32. Lambe M, Thörn M, Sparén P, Bergström R, Adami HO. Malignant melanoma: reduced risk associated with early childbearing and multiparity. Melanoma Res 1996; 6: 147-53.
33. Persson I, Yuen J, Bergkvist L, Schairer C. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy--long-term follow-up of a Swedish cohort. Int J Cancer 1996; 67: 327-32.
34. Westerdahl J, Olsson H, Måsbäck A, Ingvar C, Jonsson N. Risk of malignant melanoma in relation to drug intake, alcohol, smoking and hormonal factors. Br J Cancer 1996; 73:1126-31.
35. Smith MA, Fine JA, Barnhill RL, Berwick M. Hormonal and reproductive influences and risk of melanoma in women. Int J Epidemiol 1998; 27: 751-7.
36. Feskanich D, Hunter DJ, Willett WC, Spiegelman D, Stampfer MJ, Speizer FE, Colditz GA. Oral contraceptive use and risk of melanoma in premenopausal women. Br J Cancer 1999; 81: 918-23.
37. Young P, Purdie D, Jackman L, Molloy D, Green A. A study of infertility treatment and melanoma. Melanoma Res 2001; 11: 535-41.
38. Fernandez E, Gallus S, Bosetti C, Franceschi S, Negri E, La Vecchia C. Hormone replacement therapy and cancer risk: a systematic analysis from a network of case-control studies. Int J Cancer 2003; 105: 408-12.
39. Althuis MD, Scoccia B, Lamb EJ, Moghissi KS, Westhoff CL, Mabie JE, Brinton LA. Melanoma, thyroid, cervical, and colon cancer risk after use of fertility drugs. Am J Obstet Gynecol 2005; 193: 668-74.
40. Naldi L, Altieri A, Imberti GL, Giordano L, Gallus S, La Vecchia C; Oncology Study Group of the Italian Group for Epidemiologic Research in Dermatology (GISED). Cutaneous malignant melanoma in women. Phenotypic characteristics, sun exposure, and hormonal factors: a case-control study from Italy. Ann Epidemiol 2005; 15: 545-50.
41. Neale RE, Darlington S, Murphy MF, Silcocks PB, Purdie DM, Talbäck M. The effects of twins, parity and age at first birth on cancer risk in Swedish women. Twin Res Hum Genet 2005; 8: 156-62.
42. Vessey M, Painter R. Oral contraceptive use and cancer. Findings in a large cohort study, 1968-2004. Br J Cancer 2006; 95: 385-9.
43. Hannaford PC, Selvaraj S, Elliott AM, Angus V, Iversen L, Lee AJ. Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioner’s oral contraception study. BMJ 2007; 335: 651.
44. Corrao G, Zambon A, Conti V, Nicotra F, La Vecchia C, Fornari C, Cesana G, Contiero P, Tagliabue G, Nappi RE, Merlino L. Menopause hormone replacement therapy and cancer risk: an Italian record linkage investigation. Ann Oncol 2008; 19: 150-5.
45. Hannibal CG, Jensen A, Sharif H, Kjaer SK. Malignant melanoma risk after exposure to fertility drugs: results from a large Danish cohort study. Cancer Causes Control 2008; 19: 759-65.
46. Koomen ER, Joosse A, Herings RM, Casparie MK, Guchelaar HJ, Nijsten T. Estrogens, oral contraceptives and hormonal replacement therapy increase the incidence of cutaneous melanoma: a population-based case-control study. Ann Oncol 2009; 20: 358-64.
47. Behrens T, Kaerlev L, Cree I, Lutz JM, Afonso N, Eriksson M, Guénel P, Merletti F, Morales-Suarez-Varela M, Stengrevics A, Sabroe S, Cyr D, Llopis-González A, Gorini G, Sharkova G, Hardell L, Ahrens W. Hormonal exposures and the risk of uveal melanoma. Cancer Causes Control 2010; 21: 1625-34.
48. Kvaskoff M, Bijon A, Mesrine S, Boutron-Ruault MC, Clavel-Chapelon F. Cutaneous melanoma and endogenous hormonal factors: a large French prospective study. Am J Epidemiol 2011; 173: 1192-202.
49. Tang JY, Spaunhurst KM, Chlebowski RT, Wactawski-Wende J, Keiser E, Thomas F, Anderson ML, Zeitouni NC, Larson JC, Stefanick ML. Menopausal hormone therapy and risks of melanoma and nonmelanoma skin cancers: women’s health initiative randomized trials. J Natl Cancer Inst 2011; 103: 1469-75.
50. Stewart LM, Holman CD, Finn JC, Preen DB, Hart R. Association between in-vitro fertilization, birth and melanoma. Melanoma Res 2013; 23: 489-95.
51. Zinkhan M, Stang A, Jöckel KH, Marr A, Bornfeld N, Schmidt-Pokrzywniak A. Having children, social characteristics, smoking and the risk of uveal melanoma: a case-control study. Ophthalmic Epidemiol 2013; 20: 360-8.
52. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88.
53. Higginz JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-58.
54. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-60.
55. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-34.
56. Jeffery SL, Lewis JS. Malignant melanoma and hormone replacement therapy. Br J Plast Surg 2000; 53: 539.
57. Karagas MR, Zens MS, Stukel TA, Swerdlow AJ, Rosso S, Osterlind A, Mack T, Kirkpatrick C, Holly EA, Green A, Gallagher R, Elwood JM, Armstrong BK. Pregnancy history and incidence of melanoma in women: a pooled analysis. Cancer Causes Control 2006; 17: 11-9.
58. Osterlind A. Hormonal and reproductive factors in melanoma risk. Clin Dermatol 1992; 10: 75-8.
59. Gupta A, Driscoll MS. Do hormones influence melanoma? Facts and controversies. Clin Dermatol 2010; 28: 287-92.